Hardman & Co Life Sciences Research: Long-term Pharmaceutical Industry Cost and EBIT Analysis

London, UK – EQS Newswire – June 10, 2022 – Financial information from over 100 multinational pharmaceutical companies, including over 70,000 data points, has been accumulated over the last 35 years to create a pharmaceutical database. All of our data (sales, cost of goods sold, sales management costs, R & D and other income) is derived from annual reports, regulatory filings, and company presentations to each company’s presentation method. Regardless, it is analyzed in the same way as possible. data. This is a key differentiator from competitive products, with all corporate management teams reporting “adjusted,” “core,” or “non-GAAP” revenue in the best possible condition. Important to show yourself in. However, different inclusion / exclusion criteria in the generation of these adjustments lead to distortion and variability.

While some companies are multi-disciplinary, another key differentiator is the extraction and analysis of data for the pharmaceutical segment only. This product is unique in that it analyzes each company’s individual cost factors over time, generates a weighted average for the pharmaceutical industry, and allows industry comparisons with peers. It also generates the underlying operating profit (EBIT) for individual companies and the industry as a whole, both before and after R & D.

Historically, data from more than 100 companies has been accumulated, but due to industry integration, it currently includes only 40 companies, accounting for an estimated 76% of the global pharmaceutical industry. The main exception is Chinese companies where inadequate data is consistently available.

Current companies included in the dataset:

Click here for more information.
https://hardmanandco.com/2021-pharma-statistics-long-term-cost-underlying-ebit-analysis/

Traded as Hardman & Co, Hardman Research Ltd is an appointed representative of Capital Markets Strategy Ltd and is licensed and regulated by the Financial Conduct Authority. The FCA registration number is 600834. Hardman Research Ltd is registered with Companies House under number 8256259. Attention is paid to the important disclaimer at the end of the report.